Note: This document contains side effect information about pegcetacoplan ophthalmic. Some dosage forms listed on this page may not apply to the brand name Syfovre.
Applies to pegcetacoplan ophthalmic: intraocular solution.
Serious side effects of Syfovre
Along with its needed effects, pegcetacoplan ophthalmic (the active ingredient contained in Syfovre) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking pegcetacoplan ophthalmic:
More common
- Bloody eye
- eye pain
- painful irritation of the clear front part of the eye
- redness of the eye
Less common
- Blindness
- blurred or change in vision
- seeing flashes or sparks of light
- seeing floating spots before the eyes, or a veil or curtain appearing across part of vision
- sensitivity of the eye to light
- tearing
Rare
- Headache
- red or bloodshot eye
Other side effects of Syfovre
Some side effects of pegcetacoplan ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
- Feeling like something is in the eye
For Healthcare Professionals
Applies to pegcetacoplan ophthalmic: intravitreal solution.
General
The most common adverse reactions with frequency of 5% or greater were ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage.[Ref]
Ocular
Very common (10% or more): Ocular discomfort (13%), neovascular age-related macular degeneration (12%), vitreous floaters (10%)
Common (1% to 10%): Conjunctival hemorrhage, vitreous detachment, retinal hemorrhage, punctate keratitis, posterior capsule opacification, intraocular inflammation, intraocular pressure increased, optic ischemic neuropathy
Frequency not reported: Endophthalmitis, retinal detachment, hyphema, retinal tears[Ref]
-Ocular discomfort included eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye.
-Neovascular age-related macular degeneration included exudative age-related macular degeneration, choroidal neovascularization.
-Punctate keratitis included punctate keratitis, keratitis.
-Intraocular inflammation included vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, anterior chamber flare.[Ref]
Other
Deaths were reported in 6.7% of patients treated monthly, 3.6% of patients treated every other month and 3.8% of patients assigned to sham. The rates and causes of death were consistent with the elderly study population.[Ref]
Common (1% to 10%): Death[Ref]
